Xenetic Biosciences Enters Into Manufacturing Agreement With Catalent Pharma Solutions

Share, email, print, bookmark SOURCE reports.

In full transparency, the following is a press release

***

FRAMINGHAM – Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, yesterday, July 7, announced it has entered into a manufacturing agreement with Catalent Pharma Solutions LLC (“Catalent”), which will include cGMP manufacturing for the Company’s recombinant protein, Human DNase I.

Catalent is the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities.

“We are pleased to be working with a preeminent contract development and manufacturing organization such as Catalent, and to have the opportunity to leverage their broad expertise and successful track record with early-stage development through commercial manufacturing. We are excited to take this step forward on the path to the clinic and look forward to investigating systemic DNase as an adjunctive therapy for locally advanced or metastatic cancers,” commented, Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

“This agreement is an important step towards long-term collaboration betweenCatalent and Xenetic,” added Vikalp Mohan, Global Vice President, Head of Drug Substance at Catalent Biologics. “We look forward to leveraging Catalent’s proven biomanufacturing expertise at our site in Madison, Wisconsin to support the advancement of Xenetic’s DNase clinical development program and accelerating their path to first-in-human studies.”

Xenetic’s interventional DNase based oncology platform is aimed at improving outcomes of existing treatments, including immunotherapies. The Company exclusively licensed intellectual property for uses of DNases in cancer include systemic co-administration of DNases along with standard therapies, including chemotherapy, radiation and checkpoint inhibitors, or along with conventional chimeric antigen receptor (CAR) T therapies.

The DNase platform is designed to target neutrophil extracellular traps (“NETs”), which are weblike structures composed of extracellular chromatin coated with histones and other proteins. NETs are expelled by activated neutrophils, in response to microbial or pro-inflammatory challenges. However, excessive production or reduced clearance of NETs can lead to aggravated inflammatory and autoimmune pathologies, as well as creation of pro-tumorigenic niches in the case of cancer growth and metastasis.

The Company is working toward its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.

Catalent enables pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is the industry’s preferred partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 19,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications. The Company’s DNase oncology platform, in development for the treatment of solid tumors, is aimed at improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs). The Company is also developing its personalized CAR T platform technology, XCART™, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-Cell lymphomas. The company has its headquarters in Framingham.

editor

email: editor@FraminghamSource.com call or text at 508-315-7176


Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/framin10/public_html/wp-includes/functions.php on line 5279

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/framin10/public_html/wp-content/plugins/really-simple-ssl/class-mixed-content-fixer.php on line 107